Noxopharm (ASX: NOX) today announces presentation of a poster concerning its DARRT-1 clinical study to the Annual Scientific Meeting of the Australia and New Zealand Urogenital and Prostate Cancer (ANZUP) Clinical Trials Group being held in Sydney.
The presentation discusses the design of the DARRT-1 Phase 1b study, along with interim safety data.
For further information please download PDF attached:
Download this document
